Erik Wambre1, Jonathan H DeLong1, Eddie A James1, Nadia Torres-Chinn1, Wolfgang Pfützner2, Christian Möbs2, Stephen R Durham3, Stephen J Till4, David Robinson5, William W Kwok6. 1. Benaroya Research Institute at Virginia Mason, Seattle, Wash. 2. Department of Dermatology and Allergology, University Medical Center, Marburg, Germany. 3. Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College, London, United Kingdom. 4. Allergy, Asthma and Lung Biology, King's College London, London, United Kingdom. 5. Virginia Mason Medical Center, Seattle, Wash. 6. Benaroya Research Institute at Virginia Mason, Seattle, Wash; Department of Medicine, University of Washington, Seattle, Wash. Electronic address: bkwok@benaroyaresearch.org.
Abstract
BACKGROUND: Understanding the mechanisms by which the immune system induces and controls allergic inflammation at the T-cell epitope level is critical for the design of new allergy vaccine strategies. OBJECTIVE: We sought to characterize allergen-specific T-cell responses linked with allergy or peripheral tolerance and to determine how CD4(+) T-cell responses to individual allergen-derived epitopes change over allergen-specific immunotherapy. METHODS: Timothy grass pollen (TGP) allergy was used as a model for studying grass pollen allergies. The breadth, magnitude, epitope hierarchy, and phenotype of the DR04:01-restricted TGP-specific T-cell responses in 10 subjects with grass pollen allergy, 5 nonatopic subjects, and 6 allergy vaccine-treated subjects was determined by using an ex vivo peptide-MHC class II tetramer approach. RESULTS: CD4(+) T cells in allergic subjects are directed to a broad range of TGP epitopes characterized by defined immunodominance hierarchy patterns and with distinct functional profiles that depend on the epitope recognized. Epitopes that are restricted specifically to either TH2 or TH1/TR1 responses were identified. Allergen-specific immunotherapy was associated with preferential deletion of allergen-specific TH2 cells and without a significant change in the frequency of TH1/TR1 cells. CONCLUSIONS: Preferential allergen-specific TH2 cell deletion after repeated high-dose antigen stimulation can be another independent mechanism to restore tolerance to allergen during immunotherapy.
BACKGROUND: Understanding the mechanisms by which the immune system induces and controls allergic inflammation at the T-cell epitope level is critical for the design of new allergy vaccine strategies. OBJECTIVE: We sought to characterize allergen-specific T-cell responses linked with allergy or peripheral tolerance and to determine how CD4(+) T-cell responses to individual allergen-derived epitopes change over allergen-specific immunotherapy. METHODS: Timothy grass pollen (TGP) allergy was used as a model for studying grass pollen allergies. The breadth, magnitude, epitope hierarchy, and phenotype of the DR04:01-restricted TGP-specific T-cell responses in 10 subjects with grass pollen allergy, 5 nonatopic subjects, and 6 allergy vaccine-treated subjects was determined by using an ex vivo peptide-MHC class II tetramer approach. RESULTS: CD4(+) T cells in allergic subjects are directed to a broad range of TGP epitopes characterized by defined immunodominance hierarchy patterns and with distinct functional profiles that depend on the epitope recognized. Epitopes that are restricted specifically to either TH2 or TH1/TR1 responses were identified. Allergen-specific immunotherapy was associated with preferential deletion of allergen-specific TH2 cells and without a significant change in the frequency of TH1/TR1 cells. CONCLUSIONS: Preferential allergen-specific TH2 cell deletion after repeated high-dose antigen stimulation can be another independent mechanism to restore tolerance to allergen during immunotherapy.
Authors: Christian Möbs; Henrik Ipsen; Lea Mayer; Caroline Slotosch; Arnd Petersen; Peter A Würtzen; Michael Hertl; Wolfgang Pfützner Journal: J Allergy Clin Immunol Date: 2012-09-27 Impact factor: 10.793
Authors: S R Durham; S M Walker; E M Varga; M R Jacobson; F O'Brien; W Noble; S J Till; Q A Hamid; K T Nouri-Aria Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245
Authors: Erik Wambre; Jonathan H DeLong; Eddie A James; Rebecca E LaFond; David Robinson; William W Kwok Journal: J Allergy Clin Immunol Date: 2011-10-05 Impact factor: 10.793
Authors: Carla Oseroff; John Sidney; Maya F Kotturi; Ravi Kolla; Rafeul Alam; David H Broide; Stephen I Wasserman; Daniela Weiskopf; Denise M McKinney; Jo L Chung; Arnd Petersen; Howard Grey; Bjoern Peters; Alessandro Sette Journal: J Immunol Date: 2010-06-16 Impact factor: 5.422
Authors: Amedee Renand; Mohamed H Shamji; Kristina M Harris; Tielin Qin; Erik Wambre; Guy W Scadding; Peter A Wurtzen; Stephen J Till; Alkis Togias; Gerald T Nepom; William W Kwok; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2017-11-09 Impact factor: 10.793
Authors: V Schulten; V Tripple; K Aasbjerg; V Backer; G Lund; P A Würtzen; A Sette; B Peters Journal: Clin Exp Allergy Date: 2016-03 Impact factor: 5.018
Authors: Amedee Renand; Luis D Archila; John McGinty; Erik Wambre; David Robinson; Belinda J Hales; Wayne R Thomas; William W Kwok Journal: J Allergy Clin Immunol Date: 2015-09-11 Impact factor: 10.793